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Abstract
Background & Aims: Because of the lack of objective tests to diagnose drug-
induced liver injury (DILI), causality assessment is a matter of debate. Expert
opinion is often used in research and industry, but its test–retest reliability is
unknown. To determine the test–retest reliability of the expert opinion pro-
cess used by the Drug-Induced Liver Injury Network (DILIN). Methods:
Three DILIN hepatologists adjudicate suspected hepatotoxicity cases to one
of five categories representing levels of likelihood of DILI. Adjudication is
based on retrospective assessment of gathered case data that include prospec-
tive follow-up information. One hundred randomly selected DILIN cases
were re-assessed using the same processes for initial assessment but by three
different reviewers in 92% of cases. Results: The median time between
assessments was 938 days (range 140–2352). Thirty-one cases involved >1
agent. Weighted kappa statistics for overall case and individual agent cate-
gory agreement were 0.60 (95% CI: 0.50–0.71) and 0.60 (0.52–0.68) respec-
tively. Overall case adjudications were within one category of each other 93%
of the time, while 5% differed by two categories and 2% differed by three cat-
egories. Fourteen per cent crossed the 50% threshold of likelihood owing to
competing diagnoses or atypical timing between drug exposure and
injury. Conclusions: The DILIN expert opinion causality assessment method
has moderate interobserver reliability but very good agreement within one
category. A small but important proportion of cases could not be reliably
diagnosed as ≥50% likely to be DILI.
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In 2004, the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) established the Drug-
Induced Liver Injury Network (DILIN) as a multicentre
study with aims of improving the understanding of the
causes, outcomes and molecular mechanisms of hepato-
toxicity owing to medications or herbal and dietary sup-
plements (HDS) (1). The Network of eight centres has
enrolled >1200 patients into the Prospective Study.
Cases meeting laboratory enrolment criteria are enrolled
at the discretion of the investigators at each site and
based on their clinical suspicion that such abnormalities
are at least possibly owing to DILI. Each case has a clini-
cal narrative and a formatted file of demographics, med-
ications, radiography data, histology (when available)
and laboratory values in flow sheet format. Serum,
plasma and DNA are also collected.
Because there are no objective diagnostic tests, DILI
remains a diagnosis of exclusion that requires adequate
clinical, laboratory and imaging data. Scoring algo-
rithms for diagnosis are available (2–4), but retest reli-
ability studies are quite limited. Roussel Uclaf Causality
Assessment Method (RUCAM) that was developed
under the auspices of the Council for International
Organizations of Medical Sciences (CIOMS) is the most
widely accepted and validated instrument, yet only one
study has examined its retest reliability (5). For research
purposes, DILIN uses a standardized procedure for
expert opinion consensus to adjudicate the likelihood of
DILI that is based in part on RUCAM and yields similar
categories of DILI likelihood (6). However, reliability of
the DILIN expert opinion process has not been critically
assessed. Poor reliability would undermine any future
mechanistic studies using serum, plasma or DNA from
the DILIN subjects and undermine the use of DILIN
cases for development of other more accessible diagnos-
tic algorithms for the clinician. Therefore, the aim of
this analysis was to assess the interrater, test–retest reli-
ability of the DILIN consensus opinion process.
Methods
DILIN prospective cohort
The DILIN study has been previously described in detail
(6). Patients suspected of having liver injury owing to
medications or HDS products were enrolled within
24 weeks of injury onset and then followed up prospec-
tively for 6–24 months depending on the pace and com-
pleteness of DILI resolution. Because the enrolment
window was 24 weeks, cases enrolled at varying time
points in their DILI event. Enrolment criteria were (1)
serum alanine aminotransferase (ALT) or aspartate ami-
notransferase (AST) levels > 5 times the upper limit of
the normal (ULN) (or pretreatment baseline if abnor-
mal) on two consecutive occasions, or (2) alkaline phos-
phatase (AP) levels > twice the ULN (or pretreatment
baseline if abnormal) on two consecutive occasions, or
(3) total serum bilirubin > 2.5 mg/dl, or international
normalized ratio (INR) >1.5 with any elevation in
serum ALT, AST or AP. Cases meeting laboratory enrol-
ment criteria are enrolled at the discretion of the investi-
gators at each site and based on their clinical opinion.
Case enrolment is not restricted by time of onset
because some medications are well known to have very
long latencies of even years (e.g. nitrofurantoin). We
did not restrict enrolment to those with full follow-up
data showing resolution of injury (i.e. dechallenge)
because such restriction would hinder the prospective
nature of DILIN. We wanted to capture this dechallenge
data while under study protocol. Injury pattern was cat-
egorized as cholestatic (R < 2), mixed (R 2–5) or hepa-
tocellular (R > 5) where R = (ALT/ULN)  (AP/
ULN). Severity level was based on INR, bilirubin, signs
of liver failure, need for hospitalization and fatal or
transplant outcome as previously described (6). Exclu-
sion criteria included acetaminophen hepatotoxicity,
prior liver or bone marrow transplant, alcohol-related
liver disease, autoimmune hepatitis or genetic liver dis-
ease. Patients with compensated chronic hepatitis B, C
or with nonalcoholic fatty liver disease were eligible and
enrolled at the discretion of the site investigators. For
patients with such background liver disease, reviewers
used baseline liver enzyme levels, viral serologies and
viral nucleic acid tests to judge the presence of DILI vs.
exacerbation of underlying liver disease.
At baseline visit, a detailed history was obtained, and
clinical, laboratory and imaging results were extracted
from records. As reported previously, a DILIN protocol
battery of tests to exclude other causes of liver injury
was obtained at enrolment if not extractable from chart
records (6). Serum, plasma, urine and DNA specimens
were sent to a central repository for future studies. Sub-
jects were followed up for at least 6 months and those
with persistent liver abnormalities or signs of chronic
liver injury were followed up through 24 months.
Ninety (90%) of the cases had complete documenta-
tion of data for all 21 parameters adapted from Agarwal
et al. as essential data for DILI cases (7). (Appendix fig-
ure) Nine (9%) were missing complete data for one
parameter each (four cases – incomplete viral serologies,
four cases – no documented hepatic imaging, one case –
incomplete ‘washout’ of liver biochemistries); one case
(1%) was missing complete data for two parameters,
viral serologies and autoimmune markers. This last case
was considered unlikely to be DILI in large part owing
to lack of these data. Overall, the 90 cases with complete
data were considered more likely to be DILI than the 10
cases with incomplete data (median DILIN scores of 2
vs. 3, respectively, P = 0.04).
DILIN expert opinion process
DILIN causality assessment has been described in detail
(6). The process is the same for medication and HDS
hepatotoxicity, as there are little data to suggest that a
different causality process is necessary or valid. Each
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case was adjudicated independently by three hepatolo-
gists including the site investigator who enrolled the
case. Assessment is based on retrospective review of the
case history, laboratory data and prospective follow-up
study visits. Each reviewer assigns a causality score cor-
responding to percentages of DILI likelihood in which
1 = definite (>95% likelihood), 2 = very likely (75–
95%), 3 = probable (50–74%), 4 = possible (25–49%)
and 5 = unlikely (<25%). Disagreements were identified
after the three reviewers submitted their scores. Consen-
sus scores were achieved by electronic mail or confer-
ence call discussions. Those cases in which agreement
could not be reached by the three reviewers were then
voted upon by one member from each DILIN site dur-
ing monthly conference calls. Final score was assigned
by majority vote. For cases involving >1 agent, an over-
all case score and separate individual scores were deter-
mined. For example, the overall case score might be 1
(definite DILI) with one agent scoring a 2 (very likely
causal) and the other scoring a 4 (only possibly).
From inception in 2004 to April 16, 2009, adjudica-
tion was based on results obtained shortly after enrol-
ment, thus simulating the clinician’s task to assess at
time of presentation. However, when enrolment
occurred within days of onset, data on resolution of
injury were sparse. After April 16, 2009, the protocol
was changed, so that adjudication was done 6 months
after enrolment and follow-up data could be included
into the assessment.
Reliability cohort and reassessment
The DILIN Data Coordinating Center chose 100 cases
by computer-driven random assignment from the Pro-
spective registry. Two cases involving the interval
development of new diagnostic information regarding
hepatitis E testing were included, but the HEV data
were specifically excluded for reassessment (8). Chosen
cases were stratified 1:1 across April 16, 2009. Group
A included 49 cases enrolled before April 16, 2009,
and Group B, 51 cases enrolled afterwards. Group A
cases did not have 6-month data for the initial assess-
ment, but these data were available for the reassess-
ment. Group B cases had 6-month data for both the
initial and reassessments. We stratified across these
two periods to examine whether reliability is influ-
enced by using follow-up data. For reassessments, 92
cases had three new reviewers. Because of an adminis-
trative error, eight cases had one previous reviewer
and two new reviewers. No cases were reassessed by
the site investigator who enrolled the case. The ratio-
nale for excluding the enrolling site investigator from
reassessments was to minimize recall bias as the
enrolling investigator is often the hepatologist who
continues to care for the patient. At least 4 months
had to elapse before a case could be selected for reas-
sessment. The process of reassessment was otherwise
the same.
Analysis
Standard descriptive statistics were used to character-
ize this cohort of 100 patients and compared to the
remaining 983 cases not selected. The original and re-
adjudication scores were compared for the 100 cases
using weighted kappa statistics owing to ordinal nat-
ure of the categories. Because some cases involved >1
drug or HDS product, the reliability at the individual
agent level was also examined. Weighted kappa statis-
tics were also determined for Group A and Group B
cases separately. Because the two categories of highest
likelihood (>95% likelihood and 75–95%) were simi-
lar in clinical and research relevance, reliability was
assessed collapsing these two categories into one, thus
creating quartiles of per cent likelihood. Score differ-
ences were categorized as 1, 2 or >2 scores apart and
direction of changes were tallied. Cases with scores
crossing the 50% likelihood line (1, 2 or 3 vs. 4
or 5) were re-examined in detail to assess factors
that might have led to such uncertainty in DILI diag-
nosis.
Results
Subjects
Among 1083 DILIN cases adjudicated by June 1, 2011,
49 assessed prior to the use of 6-month follow-up data
(Group A) and 51 assessed with the use of 6-month data
(Group B) were randomly chosen. These cases were sim-
ilar to those not chosen across a variety of clinical and
demographic variables (Table 1). Seventeen of the 100
had initial agreement without need for any discussion
whatsoever. This rate is similar to the 20.1% for the total
cohort. Of the 100 cases, 69 involved only one medica-
tion or HDS product and 31 involved multiple agents. A
total of 138 different agents were implicated. The origi-
nal causality scores were similar between Groups A and
B (Table 2).
Reliability of the DILIN expert opinion causality
assessment process
The median time between initial and reassessment was
938 days (range 140–2352). Cross-tabulation of scores
between original assessment and reassessment is shown
in Table 2a. Weighted kappa statistic for score agree-
ment for overall DILI diagnosis was 0.60, 95% confi-
dence interval (CI) 0.50–0.71. Kappa for the 69 single
agent cases and 138 individual agent scores were similar
[0.59 (0.46–0.71) and 0.60 (0.52–0.68)]. Score agree-
ment tended to be better for Group B compared with
Group A for overall case scores [0.67 (0.38–0.81) vs.
0.53 (0.38–0.68)], single agent cases [0.69 (0.53–0.85)
vs. 0.49 (0.31–0.68)] and individual agent scores [0.66
(0.56–0.76) vs. 0.49 (0.34–0.63)], although the differ-
ences did not reach statistical significance. Combining
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score categories 1 and 2 into one category did not
change the kappa score for overall case score [0.60
(0.48–0.72)], but the kappa for Group B increased to
0.73 (0.59–0.87), while the kappa for Group A fell to
0.44 (0.27–0.61) (Table 2b). Excluding the eight cases
that had one repeat reviewer on reassessment did
not change the kappa scores significantly (data not
shown).
Table 1. Features of DILIN cases randomly selected for reassessment compared with cases not reassessed
Characteristic
Cases reassessed Cases not reassessed
P-valueN = 100 N = 983
Demographics
Age
Mean (SD) 50.0 (18.59) 48.8 (17.01) 0.41
Gender
Female 63 (63.0%) 558 (56.8%) 0.24
Race (self report)
Caucasian 78/100 (78.0%) 764/973 (78.5%)
Black 12/100 (12.0%) 113/973 (11.6%) 0.96
Asian 3/100 (3.0%) 36/973 (3.7%)
Other/Multiracial 7/100 (7.0%) 60/973 (6.2%)
Body mass index (BMI)
Number w/BMI 88 917
Mean (SD) 27.0 (6.89) 27.4 (6.50) 0.39
Liver Injury
Categorized days from primary drug start to DILI onset
≤1 week 7/88 (8.0%) 81/813 (10.0%)
2–4 weeks 29/88 (33.0%) 255/813 (31.4%)
5–12 weeks 26/88 (29.5%) 272/813 (33.5%) 0.84
13–24 weeks 11/88 (12.5%) 85/813 (10.5%)
>24 weeks 15/88 (17.0%) 120/813 (14.8%)
No. of concomitant drugs in the 2 months prior to DILI onset
0–2 24/93 (25.8%) 191/824 (23.2%)
3–5 25/93 (26.9%) 223/824 (27.1%) 0.83
>5 44/93 (47.3%) 410/824 (49.8%)
Pattern of liver injury at onset or earliest after onset*
Cholestatic (R < 2) 25/100 (25.0%) 248/974 (25.5%)
Mixed (R 2–5) 17/100 (17.0%) 207/974 (21.3%) 0.59
Hepatocellular (R > 5) 58/100 (58.0%) 519/974 (53.3%)
Peak values between DILI onset and 6 months after enrolment
ALT (U/L)
Mean (SD) 1118 (1887) 998 (1481) 0.90
Alkaline Phosphatase (U/L)
Mean (SD) 390 (381) 410(418) 0.33
Total Bilirubin (mg/dl)
Median (25th, 75th) 9.0 (1.7, 22.9) 9.7 (2.7, 19.5) 0.94
INR
Mean (SD) 2.1 (2.49) 1.6 (1.41) 0.07
Adjudication
Overall causality score
Definite Greater than 95% 23/100 (23.0%) 173/744 (23.3%)
Very likely 75–95% 39/100 (39.0%) 312/744 (41.9%)
Probable 50–75% 19/100 (19.0%) 141/744 (19.0%) 0.22
Possible 25–50% 10/100 (10.0%) 91/744 (12.2%)
Unlikely Less than 25% 9/100 (9.0%) 27/744 (3.6%)
Outcomes
DILIN severity score(6)
Mild 23/100 (23.0%) 185/744 (24.9%)
Moderate 19/100 (19.0%) 156/744 (21.0%)
Moderate-hospitalized 35/100 (35.0%) 221/744 (29.7%) 0.36
Severe 12/100 (12.0%) 129/744 (17.3%)
Fatal 11/100 (11.0%) 53/744 (7.1%)
*R = (ALT/ULN)  (AP/ULN).
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Magnitude of disagreement
The magnitude of disagreement on reassessment was
small. Ninety three percent of overall scores were the
same or differed by only one point (92% for Group A;
94% for Group B). (Fig. 1a). When scores 1 and 2 were
combined into one category, 95 of 100 were within one
score (92% for Group A; 98% for Group B). (Fig. 1b).
Direction of disagreement
Overall causality reassessment scores had a lower likeli-
hood of DILI compared with the initial evaluation
scores, with a reduction in the average initial score –
average reassessment score of 0.22 (range from 3 to
2). Of the 45 cases where scores differed, 15 were con-
sidered more likely to be DILI, while 30 were considered
less likely to be DILI on reassessment. Direction of
changes was similar between groups (Group A: 7 more
likely, 17 less likely; Group B: 8 more likely, 13 less
likely; P = ns).
Because there were more cases originally scoring 1–2
(62%) than 4–5 (19%) reflecting the careful consideration
of other potential causes for liver injury before enrolment,
the DILIN cohort was prone to a ceiling effect. Therefore,
we looked at cases originally scoring in the middle as well
as proportionate increases vs. decreases in the reassess-
ment scoring of cases originally scoring a 2 or 4 respec-
tively. Cases initially scored as a 3 still tended to score
less likely to be a DILI event (42% vs. 32%), and cases
originally scoring 2 were reassessed as less likely to be
DILI proportionately more often than cases scoring 4
were reassessed as more likely (33% vs. 20%). (Table 3).
Cases crossing the 50% likelihood on reassessment
There were 14 (14%) cases with scores that crossed the
50% likelihood threshold on reassessment (scores 1–3
Table 2. Original and reassessment score frequencies and kappa statistics for Groups A, B and total cohort. (a) 5-point likelihood scale
(b) 4-point likelihood scale, combining categories 1 and 2
Reassessment score frequencies
(a)
1 2 3 4 5 Totals Kappa (95% CI)
Original score frequencies Group A
n = 49
1 9 3 0 1 0 13 0.53 (0.38–0.88)
2 0 12 6 1 1 20
3 0 3 1 3 1 8
4 0 0 1 3 1 5
5 0 0 0 3 0 3
Group B
n = 51
1 6 3 1 0 0 10 0.67 (0.53–0.81)
2 4 10 4 1 0 19
3 1 2 4 4 0 11
4 0 0 1 4 0 5
5 0 0 0 0 6 6
Groups A & B
n = 100
1 15 6 1 1 0 23 0.60 (0.50–0.71)
2 4 22 10 2 1 39
3 1 5 5 7 1 19
4 0 0 2 7 1 10
5 0 0 0 3 6 9
(b)
1 or 2 3 4 5 Totals Kappa (95% CI)
Original score frequencies Group A
n = 49
1 or 2 24 6 2 1 33 0.44 (0.27–0.61)
3 3 1 3 1 8
4 0 1 3 1 5
5 0 0 3 0 3
Group B
n = 51
1 or 2 23 5 1 0 29 0.73 (0.58–0.87)
3 3 4 4 0 11
4 0 1 4 0 5
5 0 0 0 6 6
Groups A & B
n = 100
1 or 2 47 11 3 1 62 0.6 (0.48–0.72)
3 6 5 7 1 19
4 0 2 7 1 10
5 0 0 3 6 9
1 = definite (>95% likelihood), 2 = very likely (75–95%), 3 = probable (50–74%), 4 = possible (25–49%), 5 = unlikely (<25%).
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vs. 4–5). Eight cases were from Group A and 6 from
Group B (P = ns). In these 14 cases, 12 scores crossed
below the 50% threshold, while only two crossed the
line towards more likely DILI (Table 4). Nine of 14
(64%) differed by one point only (i.e. between 3 and 4),
but five differed by >1 point. Eleven involved only one
drug or HDS product. No implicated agents appeared
more than once in these 14 cases. Although not statisti-
cally significant (P = 0.51), the reassessment score dif-
fered from the site investigator’s initial assessment score
more often (12 of 14) than it did for the other two ini-
tial reviewers (9 of 14 for both).
Review of these 14 cases and recorded comments by
reviewers suggest two major reasons for diagnostic
uncertainty. Four cases had uncertain or inconsistent
timing between agent exposure and liver injury; seven
had competing diagnoses and one had both reasons
(Table 4).
Discussion
The DILIN expert opinion process for causality assess-
ment has moderate test–retest reliability on a 5-point
scale of likelihood, but agreement within one category
of likelihood was very good at 93% of cases. Inclusion of
6-month follow-up data tended to improve concor-
dance, suggesting that diagnostic reliability probably
improves when longer follow-up is available. These data
are critical in establishing the DILIN registry as a source
of tissue and serum for mechanistic studies. These data
also help establish the registry as a reliable source of
cases for the development of diagnostic instruments that
are clinically accessible. While consensus expert opinion
may be a reliable diagnostic method, it is cumbersome,
inaccessible to the clinician and used only for research
purposes. Development of a computerized diagnostic
tool for clinicians will need large registries of reliably
diagnosed cases (9).
The reliability of the DILIN consensus process is bet-
ter than that reported for individual assessments with-
out consensus. Studies of reliability between individuals
diagnosing adverse drug reactions of all types yield
kappa statistics as low as 0.05–0.2. The consensus pro-
cess used by DILIN substantially elevates the interrater
reliability (kappa 0.60). The consensus of three review-
ers per case attenuates individual biases and variations
in experience. Moreover, the collective experience and
expertise of the larger causality committee (15–25 hepa-
tologists per call) is brought to bear on cases where the
three reviewers cannot agree. Thus, the consensus pro-
cess elevates the test–retest reliability to a level compara-
ble to that reported for histological liver diagnoses that
also rely on consensus expert opinion. Chronic viral
hepatitis biopsies reviewed by four expert liver histopa-
thologists produced kappa statistics for disease activity
and fibrosis of 0.43 and 0.59 respectively (10). Similar
reliability results were observed for the histological
Table 3. Direction of score changes on reassessment stratified by
original score
Original score N Less likely DILI More likely DILI No change
1 23 35% NA* 65%
2 39 33% 10% 57%
3 19 42% 32% 26%
4 10 10% 20% 70%
5 9 NA* 33% 67%
*NA = not applicable.
5-point likelihood scoring scale
57%
35%
6%
2%
51%
41%
4%
4%
59%
35%
6%
73%
25%
2%4-point likelihood scoring scale
Same score
1 pt. difference
2 pt. difference
3 pt. difference
Group A
Group A
Group B
Group B
(A)
(B)
Fig. 1. Magnitude of differences between original and reassessment scores expressed as percentages of cases with 0, 1, 2 and 3 point dif-
ferences. There were no cases differing by four points. Groups A and B shown separately. (A) Percentages for the 5-point likelihood scoring
scale. (B). Percentages for a 4-point likelihood scoring scale that combines scores 1 and 2.
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diagnosis of NASH (kappa of 0.61) (11). Therefore, if
DILI diagnosis by expert opinion is to be considered as
reliable as interpretation of liver biopsies, our data suggest
that a rigorous consensus process must be incorporated.
Reliability measured by weighted kappa and per cent
agreement within one score were consistently better in
Group B for overall case and individual agent scores,
although the differences did not reach statistical signifi-
cance probably as a result of small sample size. Group
A’s lack of requirement of 6-month follow-up data is a
significant handicap as most medical diagnoses become
more reliable over time. In addition, operational vari-
ability probably decreased over time as the DILIN
reviewers became more familiar with the scoring scale
and consensus process. For these reasons, Group B more
accurately reflects the DILIN’s current reliability. When
categories 1 and 2 were combined, the kappa for Group
B improved to 0.73 with 98% of case reassessments
being within one score of each other.
Cases originally scoring in the middle of the scale at 3
were most likely to have different scores on reassessment
(Table 4) probably as a result of less certainty of DILI
diagnosis as well as being midway in a 5-point scale.
Reassessment scoring tended to decrease as opposed to
increase in likelihood of DILI (Table 4). Exclusion of
the enrolling site investigator from reassessment may
have contributed to this finding, because the site investi-
gator was often the hepatologist who also provided clin-
ical care to the patient. Such first-hand knowledge of
the case may provide more accurate causality assessment
and thereby provide the site investigator a stronger posi-
tion from which to advocate for a particular score
during discussions. Nevertheless, the consensus process
is robust enough to still produce reasonable kappa val-
ues and very close agreement within one score without
first-hand knowledge of the cases on reassessment.
As with any diagnostic tool, DILIN expert opinion is
prone to interval discoveries. Recently, a small percent-
age of DILI cases were discovered to have evidence of
acute hepatitis E virus (HEV) infection. (8, 12). Two
patients included in this study had data on hepatitis E
infection discovered between the two assessments. For
studying retest reliability of the DILIN processes only, we
expunged this HEV data from the documents reviewed
by the second set of reviewers. However, accuracy man-
dates that such interval discoveries be continually incor-
porated and cases reassessed as were done for the DILIN
HEV cases (8). This reassessment process and updating
of scores is built into the DILIN protocol. Concerns over
such changes should not halt efforts to accrue cases and
model diagnostic instruments using the DILIN registry
for training and validation purposes. Ideally, any new
diagnostic models for clinicians should be malleable
enough to incorporate new discoveries as they become
available.
DILIN cases vary in complexity particularly with
regard to whether or not competing causes of liver
injury are identified. The 14 (14%) cases that could not
be reliably diagnosed as DILI with at least 50% certainty
(i.e. cases crossing between 3 and 4 on reassessment)
were some of the more complicated cases that had
equivocal presenting diagnostic or longitudinal data.
Because these complex cases are a part of clinical
practice, a detailed examination of them may guide the
Table 4. Agents, scores and causes for DILI diagnosis uncertainty in cases crossing the 50% likelihood threshold on reassessment
No. Agents Initial score
Reassessment
score
Potential reasons for
DILI diagnosis uncertainty
1 Ranitidine 2 4 Timing
Competing diagnosis
Short latency (2 days); choledocholithiasis
2 Duloxetine 1 4 Competing diagnosis Biliary obstruction
3 Topiramate 2 5 Competing diagnosis Hepatitis C, acute
4 Cefuroxime/Nystatin 3 4 Competing diagnosis Autoimmune hepatitis
5 Cephalexin/Levofloxacin 3 5 Competing diagnosis Hepatitis C, chronic
6 Experimental agent 4 3 Competing diagnosis Ischaemic hepatopathy
7 Ezetimibe/Simvastatin 3 4 Competing diagnosis Occult alcohol
8 Sulfamethoxazole-Trimethoprim 2 4 Timing Unclear timing from drug exposure to
elevated liver enzymes
9 Ceftriaxone/Ampicillin-Sulbactam/
Fluconazole
3 4 Competing diagnosis Ischaemic hepatopathy; occult
acetaminophen overdose
10 Ciprofloxacin 4 3 Competing diagnosis Hepatitis, atypical viral (giant cell)
11 HydroxycutTM (HDS*) 3 4 Timing Long latency (approximately 75 days)
after stopping agent
12 Azithromycin 3 4 Competing diagnosis Ischaemic hepatopathy; occult
acetaminophen overdose
13 Ultra VitalityTM (HDS*) 3 4 Timing Long latency (approximately 2190 days)
while on agent
14 6-Mercaptopurine 3 4 Timing Unclear timing from drug exposure to
elevated liver enzymes
*Herbal Dietary Supplement.
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building of an accessible diagnostic instrument for clini-
cians. None of these 14 cases involved isoniazid (INH)
or amoxicillin-clavulanate, although these drugs were
the two most frequently implicated in the DILIN regis-
try accounting for >15% of all cases (13). The well-
established signature patterns of injury for these agents
(14–16) probably make DILI easier to adjudicate on one
side or the other of the 50% threshold. Giving more
weight to such signature presentations may improve the
reliability of future diagnostic algorithms.
An alternative cause of liver injury was identified in
10 of the 14 cases and many of these alternative diagno-
ses lack objective, confirmatory tests (e.g. ischaemic
hepatitis, alcohol-related liver injury). Alternative diag-
noses are well known to complicate attribution of a liver
injury to a specific medication or herbal product (17,
18). Incorporation of diagnostic criteria for competing
disorders (e.g. International Autoimmune Hepatitis
Group diagnostic criteria) (19) in expert opinion and
future causality instruments may improve reliability in
such cases. Expert opinion struggled with missing of
precise data on timing of liver enzyme abnormalities
and agent exposure in five cases. Perhaps, clear-cut tim-
ing of agent start and stop and enzyme elevation should
be a minimum requirement for assessment akin to min-
imum requirements suggested for DILI case reporting
(20). Rare or unknown hepatotoxicity may have con-
tributed to uncertainty in two cases (ranitidine and an
experimental agent), so it would be useful to have stan-
dardized scoring of published data that is more precise
than what is found in RUCAM. The LiverTox on-line
textbook developed by the NIDDK, National Library of
Medicine and DILIN contains an extensive listing of
publications related to DILI attributed to several hun-
dred agents (http://livertox.nih.gov/index.html). This
site may prove useful in standardizing assessment of
published data on a particular agent.
Progress in the prevention, early detection and treat-
ment of DILI will require well-characterized and prospec-
tively followed cases of injury attributed to specific
agents. Only with large registries of reliably diagnosed
DILI will progress be made in determining the molecular
mechanisms of DILI. This analysis suggests that the
expert opinion causality assessment process used in DI-
LIN will provide a cohort in whom the majority of cases
are reliably diagnosed as DILI or not. Specifically, the
updated and now well-practised causality assessment pro-
cess yields moderate diagnostic reliability based on kappa
statistics and excellent agreement within one score.
While such internal reliability is encouraging, external
reliability among non-DILIN experts using the same
consensus process would be worth examining. The DI-
LIN experience is limited to the USA, and therefore
applicability to other countries remains unclear. The DI-
LIN expert opinion process also lacks quantitative scores
of individual characteristics that may always hinder retest
reliability. Importantly, our study does not address the
daunting problem of validity, as there is no gold stan-
dard for the diagnosis of DILI. Some have suggested
using the RUCAM followed by expert opinion in a two-
step process to enhance reliability and validity (21).
Finally, a minority of cases straddles the 50% likeli-
hood line and eludes a reliable diagnosis of DILI vs. not
DILI usually because of lack of typical presentation,
imprecise information on timing or the presence of
competing causes of liver injury. Cases scoring in this
middle range in general, but particularly when concerns
over timing or competing diagnoses are raised, will need
to be reviewed carefully if used for mechanistic studies
and deserve special attention if a more automated and
widely accessible causality assessment instrument is to
be developed.
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Appendix
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re-challenge data if done
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imaging of liver
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laboratory values*
other agents taken
physical exam
other liver diseases
other diseases
history of prior exposure to agent
history of prior drug reaction
alcohol history
symptoms
indication for agent
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Figure. Completeness of data at adjudication for parameters adapted from Agarwal et al. (7).
*Laboratory values including liver biochemistries, INR, cell count at onset and enrollment.
**Complete viral serologies for acute hepatitis A, B and C.
^Autoimmune serologies (ANA, ASMA).
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